A risk assessment on extraneous virus contamination in a viral vaccine production environment justifies waiving of in vivo testing.

For many years in vivo assays have been a corner stone in safety testing of vaccines for human use. However, there is now an increasing regulatory focus on replacement, reduction and refinement of methods involving animal use. Accordingly, European Pharmacopoeia (Ph.Eur.) monographs and chapters are currently being revised to reduce or discontinue the use of animals in safety and other testing, when such in vivo tests are not absolutely necessary to facilitate risk mitigation. In the current study, a risk assessment of extraneous agents in viral vaccine production has been carried out and it is concluded that only the handling procedures carried out by the technical personnel pose a risk for extraneous viral contamination. A list of named, potentially virulent contaminating viruses, which may have been introduced by these procedures, has been generated. Each of the viruses on this list has been evaluated for possible persistence during the production processes, and it has for all of these been concluded that, if at all present, they only present a negligible risk of introducing extraneous agents in the final product. The overall conclusion of the risk assessment of our vaccine production process is that it justifies the discontinuation of the current in vivo testing, and furthermore demonstrates that there is no need to substitute these in vivo assays with novel in vitro methods.

Elimination of interfering activity in serum samples in the Chinese hamster ovary pertussis serology assay.

An interfering substance in various frozen serum samples was observed to inhibit the adhesion of Chinese hamster ovary (CHO) cells to microplate surfaces during a CHO pertussis neutralization test, resulting in wells that lacked cells or wells with dead cells after 2 days of incubation. The interfering activity in the serum could be eliminated by (i) transferring cells to other wells after their initial incubation, (ii) adding fetal calf serum (FCS) to the sample dilution buffer, (iii) precoating microplates with FCS, or (iv) preincubating the samples at 4 degrees C for 5 days. Preincubating the samples at 4 degrees C for 5 days reduced the interfering activity in only some of the samples. Adding serum to the sample dilution buffer or precoating the microplates with serum did not influence the antibody titers in the serum samples. The method described may be used for routine applications.